Mitchell R. Smith
About
Mitchell R. Smith is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Mitchell R. Smith has authored 285 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pathology and Forensic Medicine, 103 papers in Oncology and 85 papers in Genetics. Recurrent topics in Mitchell R. Smith's work include Lymphoma Diagnosis and Treatment (120 papers), Chronic Lymphocytic Leukemia Research (82 papers) and Prostate Cancer Treatment and Research (35 papers). Mitchell R. Smith is often cited by papers focused on Lymphoma Diagnosis and Treatment (120 papers), Chronic Lymphocytic Leukemia Research (82 papers) and Prostate Cancer Treatment and Research (35 papers). Mitchell R. Smith collaborates with scholars based in United States, Canada and United Kingdom. Mitchell R. Smith's co-authors include Warner C. Greene, Brian T. Hill, Arturo Zychlinsky, Yu Chen, Tahseen Al‐Saleem, Eric D. Hsi, Juraj Bodo, Alexandru Almasan, Gaurav S. Choudhary and Ayad Al‐Katib and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
Mitchell R. Smith
280 papers receiving 7.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mitchell R. Smith United States | 44 | 2.6k | 2.6k | 2.2k | 1.7k | 1.4k | 285 | 7.7k | ||
| Stephan Dirnhofer Switzerland | 52 | 2.9k 1.1× | 3.0k 1.2× | 2.5k 1.1× | 1.5k 0.9× | 1.8k 1.3× | 176 | 8.6k | ||
| Marinus H. J. van Oers Netherlands | 53 | 1.9k 0.7× | 2.8k 1.1× | 2.8k 1.3× | 3.2k 1.9× | 2.4k 1.7× | 175 | 9.0k | ||
| Livio Trentin Italy | 49 | 1.8k 0.7× | 1.9k 0.7× | 2.5k 1.1× | 3.6k 2.1× | 2.4k 1.7× | 332 | 8.6k | ||
| Bruce A. Woda United States | 49 | 2.8k 1.0× | 2.3k 0.9× | 1.9k 0.9× | 2.1k 1.2× | 821 0.6× | 181 | 9.1k | ||
| Falko Fend Germany | 55 | 3.1k 1.2× | 4.7k 1.8× | 3.7k 1.6× | 1.5k 0.9× | 1.7k 1.2× | 413 | 11.1k | ||
| Izidore S. Lossos United States | 53 | 2.9k 1.1× | 4.3k 1.7× | 5.8k 2.6× | 2.8k 1.6× | 2.5k 1.8× | 353 | 10.8k | ||
| Christer Sundström Sweden | 54 | 3.0k 1.1× | 3.8k 1.5× | 5.0k 2.2× | 3.8k 2.2× | 3.1k 2.2× | 270 | 12.3k | ||
| Jeffrey Cossman United States | 46 | 3.3k 1.2× | 2.9k 1.1× | 3.4k 1.5× | 2.9k 1.7× | 2.4k 1.7× | 112 | 9.3k | ||
| Alain Bernheim France | 47 | 2.9k 1.1× | 1.7k 0.7× | 1.4k 0.6× | 816 0.5× | 1.1k 0.8× | 287 | 8.4k | ||
| Masao Tomonaga Japan | 50 | 2.2k 0.8× | 1.9k 0.7× | 1.3k 0.6× | 5.1k 3.0× | 1.3k 0.9× | 288 | 10.4k |
Countries citing papers authored by Mitchell R. Smith
Since
Specialization
Citations
This map shows the geographic impact of Mitchell R. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell R. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell R. Smith more than expected).
Fields of papers citing papers by Mitchell R. Smith
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mitchell R. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell R. Smith. The network helps show where Mitchell R. Smith may publish in the future.
Co-authorship network of co-authors of Mitchell R. Smith
This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell R. Smith. A scholar is included among the top collaborators of Mitchell R. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell R. Smith. Mitchell R. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Le, Kang, Jing Ping Sun, Maho Shibata, et al.. (2021). Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. Blood Advances. 5(14). 2863–2878.
2.
Hill, Brian T., Deepa Jagadeesh, Alex Garcia, et al.. (2020). Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 1–2.
3.
Hill, Brian T., Deepa Jagadeesh, Brad Pohlman, et al.. (2020). A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. Seminars in Hematology. 58(1). 35–44.
4.
Vatolin, Sergei, James G. Phillips, Babal K. Jha, et al.. (2016). Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. Cancer Research. 76(11). 3340–3350.
5.
Shah, Jatin J., Andrzej Jakubowiak, Owen A. O’Connor, et al.. (2015). Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 22(1). 34–43.
6.
Sharma, Arishya, Allison J. Janocha, Brian T. Hill, et al.. (2014). Targeting mTORC1–Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells. Molecular Cancer Research. 12(9). 1205–1215.
7.
Fayad, Luis, Fritz Offner, Mitchell R. Smith, et al.. (2013). Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology. 31(5). 573–583.
8.
Smith, Mitchell R., Hailun Li, Leo I. Gordon, et al.. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. Journal of Clinical Oncology. 30(25). 3119–3126.
9.
Cheng, Fengdong, Hongwei Wang, Pedro Horna, et al.. (2012). Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity. Cancer Research. 72(17). 4440–4448.
10.
Forero‐Torres, Andres, Sven de Vos, Brad Pohlman, et al.. (2012). Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. Clinical Cancer Research. 18(5). 1395–1403.
11.
Advani, Anjali S., Bertrand Coiffier, Myron S. Czuczman, et al.. (2010). Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. Journal of Clinical Oncology. 28(12). 2085–2093.
12.
Franz, Alexander W. E., Irma Sánchez-Vargas, Joseph Piper, et al.. (2009). Stability and loss of a virus resistance phenotype over time in transgenic mosquitoes harbouring an antiviral effector gene. Insect Molecular Biology. 18(5). 661–672.
13.
Bradley, Sarah V., Mitchell R. Smith, Teresa S. Hyun, et al.. (2007). Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies. Cancer Research. 67(18). 8923–8931.
14.
Narra, Kalyani, Hossein Borghaei, Tahseen Al‐Saleem, Martin Höglund, & Mitchell R. Smith. (2005). Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature. Leukemia Research. 30(1). 109–114.
15.
Borghaei, Hossein, Michael Millenson, Russell J. Schilder, et al.. (2004). Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non‐Hodgkin lymphoma. Cancer. 101(9). 2034–2041.
16.
Young, Nancy A., Tahseen Al‐Saleem, Hormoz Ehya, & Mitchell R. Smith. (1998). Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. Cancer. 84(4). 252–261.
17.
Young, Nancy A., Tahseen Al‐Saleem, Hormoz Ehya, & Mitchell R. Smith. (1998). Utilization of fine‐needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. Cancer. 84(4). 252–261.
18.
Smith, Mitchell R., Sandra Biggar, & Mohammad Asif Hussain. (1995). Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases.. PubMed. 55(12). 2640–4.
19.
Smith, Mitchell R.. (1992). The stability of the lactose and citrate plasmids in Lactococcus lactis subsp. lactis biovar. diacetylactis. FEMS Microbiology Letters. 96(1). 7–12.
20.
Radcliffe, Robert C., et al.. (1983). Chunkwood production: a new concept. Forest Products Journal. 33. 43–51.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Stephan Dirnhofer Breakdown of academic impact, for papers by Marinus H. J. van Oers Breakdown of academic impact, for papers by Livio Trentin Breakdown of academic impact, for papers by Bruce A. Woda Breakdown of academic impact, for papers by Falko Fend Breakdown of academic impact, for papers by Izidore S. Lossos Breakdown of academic impact, for papers by Christer Sundström Breakdown of academic impact, for papers by Jeffrey Cossman Breakdown of academic impact, for papers by Alain Bernheim Breakdown of academic impact, for papers by Masao Tomonaga